Background: The systemic use of prostaglandin E1 (PGE1) in the treatment of peripheral vascular disease is well documented. It is known that the liposomal formulation of some drugs enhances their transdermal absorption. Objective: The potential of topical application of lipid microspheres containing PGE1 (lipo-PGE1) to treat ischemic ulcers was evaluated. Methods: Lipo-PGE1 ointment (1 μg/g) was applied topically to peripheral ischemic ulcers in 10 patients for 5.8 weeks (range 4–9 weeks). The patients were followed up for 6 months, and response was assessed comparing photographs of the lesions. Results: Nine of 10 patients responded to treatment, but in 3 patients, the ulcers recurred after cessation of treatment. Conclusion: It is concluded that lipo-PGE1 ointment provides an alternative to the management of patients with incurable peripheral ischemic ulcers.

Keywords:
Ischemic peripheral ulcer, Lipid microsphere containing prostaglandin E1, Topical application, Arteriosclerosis obliterans, Thromboangiitis obliterans
This content is only available via PDF.
© 1997 S. Karger AG, Basel
1997
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.